Isis Cerezo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Isis Cerezo has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alvaro Alvarez Lopez
University of Extremadura
1 shared publication - Bárbara Cancho
Service of Nephrology, Badajoz University Hospital, 06006 Badajoz, Spain
1 shared publication Jorge Alberto Rodriguez Sabillon
Servicio de Nefrologia Hospital Universitario de Badajoz, Universidad de Extremadura Badajoz Spain
1 shared publication- Jorge Alberto Rodriguez Sabillon
Don Benito-Villanueva Hospital, Nephrology Department, 06400 Don Benito, Spain
1 shared publication - Jorge Romero
Servicio de Medicina Interna Hospital Universitario de Badajoz, Universidad de Extremadura Badajoz Spain
1 shared publication - Juan Lopez Gomez
Servicio de Bioquímica Clínica Hospital Universitario de Badajoz, Universidad de Extremadura Badajoz Spain
1 shared publication
Latest Publications
- Open Access
- 23 December 2024
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (2) , e25139
Comparative Prognostic Value of Glomerular Filtration Rate, Serum Cystatin C, Beta‐2‐Microglobulin and Albuminuria for Death and Chronic Kidney Disease Progression
Aims: Serum creatinine and albuminuria are the core of most CKD prediction and progression risk models. Several biomarkers have been introduced to improve these results such as beta‐2‐microglobulin (B2M) and cystatin C (CysC). Nevertheless, few clinical comparisons of these biomarkers are available. We have compared serum B2M levels with albuminuria, CysC levels, and the CKD‐EPI GFR equations.Designs and Methods: A sample of 434 patients were studied: 234 males and 200 females, the mean age was 58.3 ± 15.0 years, and 33.4% have diabetes mellitus. In all patients, plasma B2M, CysC, creatinine, and urinary albumin excretion were analyzed. EGFR was calculated using CKD‐EPI equations for creatinine, CysC, and creatinine‐CysC. The risk of death and CKD progression was evaluated using ROC curves and Cox proportional hazards survivorship models.Results: For mortality, the highest area under the curve (AUC) was for CysC (0.775, 0.676–0.875). The lowest sensitivity was shown by eGFR (creatinine) (0.298, 0.195–0.401, p < 0.001), eGFR (CysC) (0.216, 0.118–0.314, p < 0.001), and eGFR (creatinine + CysS) (0.218, 0.124–0.312, p < 0.001). For progression to advanced CKD, the highest AUC was for CysC (0.908, 0.862–0.954). The lowest sensitivity was shown by eGFR (creatinine) (0.184, 0.106–0.261, p < 0.001), eGFR (CysC) (0.095, 0.048–0.14, p < 0.001), and eGFR (creatinine+ CysC) (0.087, 0.040–0.134, p < 0.001). CysC, after age, was the second‐best marker of life risk. Contrariwise, for CKD progression, CysC, and albuminuria were the best markers.Conclusions: The best biomarker of mortality and risk of progression to CKD was CysC. Albuminuria and B2M were the next best options to be used. The lowest sensitivity was shown by estimated eGFR.
- 23 December 2024
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (2) , e25139
Open AccessComparative Prognostic Value of Glomerular Filtration Rate, Serum Cystatin C, Beta‐2‐Microglobulin and Albuminuria for Death and Chronic Kidney Disease Progression
Aims: Serum creatinine and albuminuria are the core of most CKD prediction and progression risk models. Several biomarkers have been introduced to improve these results such as beta‐2‐microglobulin (B2M) and cystatin C (CysC). Nevertheless, few clinical comparisons of these biomarkers are available. We have compared serum B2M levels with albuminuria, CysC levels, and the CKD‐EPI GFR equations.Designs and Methods: A sample of 434 patients were studied: 234 males and 200 females, the mean age was 58.3 ± 15.0 years, and 33.4% have diabetes mellitus. In all patients, plasma B2M, CysC, creatinine, and urinary albumin excretion were analyzed. EGFR was calculated using CKD‐EPI equations for creatinine, CysC, and creatinine‐CysC. The risk of death and CKD progression was evaluated using ROC curves and Cox proportional hazards survivorship models.Results: For mortality, the highest area under the curve (AUC) was for CysC (0.775, 0.676–0.875). The lowest sensitivity was shown by eGFR (creatinine) (0.298, 0.195–0.401, p < 0.001), eGFR (CysC) (0.216, 0.118–0.314, p < 0.001), and eGFR (creatinine + CysS) (0.218, 0.124–0.312, p < 0.001). For progression to advanced CKD, the highest AUC was for CysC (0.908, 0.862–0.954). The lowest sensitivity was shown by eGFR (creatinine) (0.184, 0.106–0.261, p < 0.001), eGFR (CysC) (0.095, 0.048–0.14, p < 0.001), and eGFR (creatinine+ CysC) (0.087, 0.040–0.134, p < 0.001). CysC, after age, was the second‐best marker of life risk. Contrariwise, for CKD progression, CysC, and albuminuria were the best markers.Conclusions: The best biomarker of mortality and risk of progression to CKD was CysC. Albuminuria and B2M were the next best options to be used. The lowest sensitivity was shown by estimated eGFR.